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Peripheral blood progenitor cell mobilization practices vary signiﬁcantly among institutions. Effective
mobilization regimens include growth factor alone, chemotherapy and growth factor combined, and, more
recently, incorporation of plerixafor with either approach. Many institutions have developed algorithms to
improve stem cell mobilization success rates and cost-effectiveness. However, an optimal stem cell mobili-
zation regimen has not been deﬁned. Practical guidelines are needed to address important clinical questions,
including which growth factor is optimal, what chemotherapy and dose is most effective, and when to initiate
leukapheresis. We present recommendations, based on a comprehensive review of the literature, from the
American Society of Blood and Marrow Transplantation.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic cell transplantation (HCT) has become an
increasingly important therapy for patients with hemato-
logic malignancies. In the past several decades, the utiliza-
tion of both autologous and allogeneic HCTs for adult and
pediatric populations has risen signiﬁcantly. Peripheral
blood progenitor cell (PBPC) mobilization and collection is a
critical part of the HCT procedure.edgments on page 1270.
quests: Hien K. Duong, MD, Blood and
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2014 American Society for Blood and Marrow
14.05.003Mobilization and collection practices vary widely. PBPC
mobilization and collection processes require involvement
and coordination of various departments, including the
clinical transplant program, therapeutic apheresis, and ﬂow
cytometry, and cell processing laboratories. Important con-
siderations regarding the choice of mobilization regimen
also include patient safety, efﬁcacy and reliability of the
regimen, physician familiarity of the regimen, patient con-
venience, and cost-effectiveness. These variables have led to
tremendous heterogeneity in practices. Institutions have
adapted strategies according to their preference and
resource availability. No standard approach has been estab-
lished, and an optimal regimen has not been deﬁned.Transplantation.
H.K. Duong et al. / Biol Blood Marrow Transplant 20 (2014) 1262e1273 1263Recently, consensus guidelines addressing autologous
stem cell mobilization strategies have been published [1].
Recognizing the need for a more standardized approach and
best practice recommendations for both autologous and
allogeneic PBPC mobilization, the Practice Guidelines Com-
mittee of the American Society for Blood and Marrow
Transplantation assembled a working group to address
important questions in this evolving ﬁeld, the answers to
which provide clinical guidelines based on the best available
evidence.
METHODS
The working group included experts in clinical transplantation and
apheresis. A list of important questions relevant to PBPC mobilization and
collection was generated. A comprehensive and critical review of relevant
published literature was then performed to address those questions. We
screened for publications in the PubMed database by including the search
terms “stem cell mobilization,” “growth factor stem cell mobilization,”
“plerixafor stem cell mobilization,” “chemotherapy stem cell mobilization,”
“pediatric stem cell mobilization,” “mobilization algorithm,” and other
search terms pertinent to the questions being addressed.
Relevant references in the publicationswere also identiﬁed and reviewed.
Both retrospective and prospective studies were included. Meeting abstracts,
data from nonepeer-reviewed journals, review articles, and studies with
incomplete data were excluded. Studies based on small sample size (<25
patients)were includedwhen they constituted theonly available data orwere
otherwise of signiﬁcant impact. Much of these data are old, some are of poor
quality, and only few are randomized, prospective studies.
One hundred eleven articles most pertinent to the proposed questions
were identiﬁed. These articles were then graded according to level of evi-
dence and strength of recommendation [2]. Technical aspects of stem cell
mobilization and collection will be addressed in future guidelines to be
published by the American Association of Blood Banks.
GUIDELINES
A summary of recommendations in the format of
frequently asked questions is also provided in Tables 1, 2,
and 3.
Allogeneic Progenitor Cell Transplant
Question 1: What is the best myeloid growth factor and dose
schedule for mobilization for adult donors?
Single-agent ﬁlgrastim (granulocyte colony-stimulating
factor [G-CSF]) is the preferred growth factor for mobilizing
peripheral blood progenitor cells (PBPCs) in healthy adult
donors. The recommended dose is 10 mg/kg bodyweight/day,
either as a single or split dose. Several studies have demon-
strated the superiority of G-CSF as a single agent compared
with granulocyte macrophage (GM)-CSF (sargramostim) or
combination growth factor support [3-15]. Equivalent split
dosing (5 mg/kg twice daily) or higher split dosing (12 mg/kg
twice daily) has been reported to result in higher collection
yields with shorter collection times; however, the toxicities
of bone pain, fatigue, and headaches were more frequent,
and costs were higher [7-10]. As a result, most centers do not
use higher doses. Similarly, when G-CSF is compared with
combination growth factor support, although a higher
number of cells may be collected, there are increased toxic-
ities and no overall beneﬁt [11-13]. A prospective random-
ized study recently compared G-CSF alone to G-CSF plus
GM-CSF and reported differential graft content without sig-
niﬁcant differences in survival [13]; the potential impact of
graft composition differences on other outcomes will need to
be explored.
Filgrastim (nonglycosylated G-CSF), which is most
commonly used in the United States, has been compared
with lenograstim (glycosylated G-CSF), which is widely used
in Europe, with similar reported outcomes [14,15]. Althoughthe longer acting pegylated G-CSF (pegﬁlgrastim) is effective,
little data support its use given the possibly increased tox-
icities and higher costs [16,17].
Plerixafor binds to and blocks the chemokine receptor
type 4 on stem cells that are thereby unanchored and able to
enter the bloodstream. Results of mobilization with single-
agent plerixafor have been reported, but the current data,
at best, indicate no beneﬁt over G-CSF alone. An ongoing
Center for International Blood and Marrow Transplant
Research study is enrolling and evaluating single-agent
plerixafor in donors [18].
For adult volunteer unrelated donors, the National
Marrow Donor Program (NMDP) performs PBSC collections
under an NMDP-sponsored research protocol, operated un-
der an Investigational New Drug application with the US
Food and Drug Administration. Under this protocol, G-CSF is
administered for 4 or 5 consecutive days at a daily dose of
10 mg/kg. The NMDP also recommends that PBSC collections
do not exceed a maximum blood volume of 24 liters,
collected over 1 or 2 consecutive days, unless approved in
advance by the NMDP medical director.
Question 2: Is PBPC mobilization with growth factors safe for
pediatric donors, and, if so, what is the best myeloid growth
factor and dose schedule?
PBPC collection is safe in healthy pediatric donors, and
target CD34þ cell yields can be achieved.
The Pediatric Blood and Marrow Transplant Consortium
conducted a retrospective analysis on the safety and efﬁcacy
of PBSC donation by 201 pediatric sibling donors from 22
institutions. The results showed that target CD34þ cell yields
were successfully achieved. Younger age, more days of
apheresis, and male gender were predictive of higher cell
yields. Growth factoreinduced pain was reported in fewer
than 15% of donors. Most donors required central venous
catheter placement, but approximately one third of children
between ages 7 and 12 years could be collected via periph-
eral access. Childrenweighing less than 20 kgwere subjected
to a single blood product exposure for priming of the
apheresis machine. Complications were generally limited
and mild [19].
There are limited data comparing mobilization regimens
in children. However, the most common approach uses
G-CSF at 10 mg/kg/day as a single daily dose or in 2 divided
doses [18-23].
Question 3: What are the target CD34þ cell doses for
collection and infusion for adult patients?
In allogeneic HCT, the importance of cell dose on trans-
plantation outcomes has been demonstrated by multiple
studies. Although the absolute lower threshold to guarantee
engraftment is not known, the generally accepted minimal
cell dose is 2  106 CD34þ cells/kg. Although some studies
have demonstrated that successful engraftment has occurred
at doses as low as 0.75  106 CD34þ cells/kg, neutrophil and,
particularly, platelet engraftment were delayed [24].
Higher doses result in faster engraftment and reduced
rates of infection and nonrelapsemortality. However, beyond
a certain threshold, there may be no added beneﬁt and a
possible increased risk of chronic graft-versus-host disease
(GVHD) [24-32]. A target CD34þ cell dose between 4 and
5  106 CD34þ cells/kg seems most reasonable based on
available data.
In 3 large studies of matched sibling donor trans-
plantation, higher cell doses were associated with faster
Table 1
Allogeneic Donors
Recommendation Grade of
Recommendation
References Comments
What is the best myeloid growth factor and dose
schedule for mobilization for adult patients?
Filgrastim (Neupogen, G-CSF)
10 mg/kg/day, as a single dose, or
5 mg/kg twice daily, with leukapheresis beginning
on the ﬁfth day
A 3-10 Split dosing has been reported to increase cell yield but is less convenient
for donors and is not typically done.
Sargramostim (Leukine, GM-CSF) B 11-13 The use of GM-CSF as single agent is not advised because CD34þ cell yields
were lower compared with G-CSF and donors required more leukapheresis
for adequate collection.
Lenograstim (Granocyte) B 14-15 No statistical difference in major outcomes between single-agent ﬁlgrastim
and lenograstim. Lenograstim not available in the US.
Pegﬁlgrastim (Neulasta) 6-12 mg/d as a single dose B 16-17 There are few reports of pegﬁlgrastim as a single agent but not widely used.
Plerixafor (Mozobil) 240 mg/kg as single agent C 18 There is currently only recent and therefore insufﬁcient evidence to more
strongly support the use of plerixafor for this indication.
Is stem cell mobilization safe and effective for
pediatric patients? What is the best myeloid
growth factor and dose schedule for pediatric
patients?
G-CSF 10 mg/kg/day either as a single daily dose,
with leukapheresis beginning on the ﬁfth day
C 19-23 Peripheral blood stem cell mobilization with growth factor support is safe
for pediatric donors.
What are the target CD34þ doses for collection
and infusion for adult patients?
For infusion:
Optimal: 4  106 CD34þ cells/kg
Maximum: 8  106 CD34þ cells/kg
For collection:
Minimum: 2  106 CD34þ cells/kg
C 24-32 A minimum threshold has not been identiﬁed. Although 2  106 CD34þ
cells/kg is generally accepted as the minimum goal, successful
transplantation has occurred at much lower doses. However, with lower
doses, there is increased risk delayed engraftment.
Several studies have shown that higher doses of CD34þ cell infusions
are associated with faster engraftment.
In the setting of matched sibling donor transplants, some studies have
shown increased risk for extensive chronic GVHD with CD34þ cell
doses above 8  106 cells/kg.
For matched unrelated donor transplants, higher cell doses have not
been associated with worsening GVHD; however, CD34þ cell doses
above 9  106 cells/kg did not result in any further survival beneﬁt.
What are the target CD34þ cells doses for
collection and infusion for pediatric patients?
For infusion:
Minimum: 2.4  106 CD34þ cells/kg
For collection:
Minimum: 2  106 CD34þ cells/kg
C 33-36 Little data regarding optimal dose. Higher stem cell dose results in
improved engraftment.
What type of venous access is recommended? For adult patients:
Antecubital venous access is preferred. If peripheral
access is not possible, central venous access may be
placed by image guidance.
C 37-41
For pediatric patients:
Most small children require central venous catheter
placement under general anesthesia. However, children
aged between 7 and 12 years should still be assessed for
possible use of peripheral vein access.
C 19, 20
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Table 2
Autologous Donors: Initial Mobilization Attempt
Recommendation Strength of
Recommendation
References Comments
What is the optimal myeloid growth factor
and dose schedule for initial mobilization
for adult patients?
For growth factor only stem cell mobilization:
Filgrastim 10 mg/kg/day, as a single dose, with leukapheresis
beginning on the ﬁfth day
A 42-46 This dose is most commonly used.
Pegﬁlgrastim 12 mg, as a single dose, with leukapheresis beginning
when the peripheral blood stem cell count is adequate (as deﬁned
below)
C 47 Although effective, not adopted by many centers.
Plerixafor and ﬁlgrastim: ﬁlgrastim 10 mg/kg/day as a single dose
with plerixafor 240 mg/kg in the afternoon or evening before
beginning leukapheresis (on day 5)
A 48-50 Because plerixafor can be prohibitively expensive, many
centers limit its use to those who are at highest risk for
mobilization failure.
For chemotherapy combined with growth factor for stem cell
mobilization:
Filgrastim 5-10 mg/kg/day, as a single dose, beginning at least 24 h
after completion of chemotherapy, and then leukapheresis
beginning when the peripheral blood stem cell count or WBC count
is adequate
A 51, 54-57 Although side effect proﬁles and other outcomes are similar,
ﬁlgrastim is more commonly used than pegﬁlgrastim.
Pegﬁlgrastim 6-12 mg/d as a single dose given at least 24 h after
completion of chemotherapy and leukapheresis beginning when
the peripheral blood stem cell count is adequate
A 52-54
What type of chemotherapy and dose is
recommended for chemomobilization in
adult patients?
Disease-speciﬁc chemotherapy (IEV, ESHAP, ICE) C 51-56 Multiple regimens appear to be feasible. Mobilization is
generally successful during count recovery after
disease-speciﬁc chemotherapy.
Cyclophosphamide C 55 Greater cell yields mobilization with G-CSF alone and able
to collect in fewer apheresis days, but increased risk of
hospitalization for neutropenic fever. Higher doses of
cyclophosphamide have been used effectively but with
more side effects and signiﬁcantly increased
hospitalizations for neutropenic fever.
Etoposide C 56, 57
What is the optimal myeloid growth factor
and dose schedule for initial mobilization
for pediatric patients?
For growth factor only stem cell mobilization:
Filgrastim 10 mg/kg/day, as a single dose, with leukapheresis
beginning on the ﬁfth day
C 58, 59 Few studies are available that compare different dose
regimens.
Plerixafor and ﬁlgrastim C 60 Only case reports are available.
For chemotherapy combined with growth factor for stem cell
mobilization:
Filgrastim 5-10 mg/kg/day as a single dose beginning at least 24 h
after completion of chemotherapy, with leukapheresis initiated
when peripheral blood stem cell count or WBC count adequate
or
Pegﬁlgrastim 100 mg/kg, as a single dose, at least 24 h after
completion of chemotherapy with leukapheresis beginning when
the peripheral blood stem cell count is adequate
C 61-63 Although both are reasonable options, ﬁlgrastim is much
more commonly used than pegﬁlgrastim.
What type of chemotherapy and dose is
recommended for chemomobilization in
pediatric patients?
Disease speciﬁc chemotherapy C 61-63 Generally can mobilize with any type of chemotherapy that
patients may currently be receiving for treatment of their
disease.
What are the target goals for collection from
adult and pediatric patients?
Minimum: 2  106 CD34þ cells/kg Optimal: 5  106 CD34þ cells/kg B 64, 65 An absolute lower threshold has not been determined, but
the generally accepted minimum is 2  106 CD34þ cells/kg.
For patients with multiple myeloma, a target CD34þ cell
dose of greater than 4  106 cells/kg is generally accepted
(for second transplant).
Higher number of cells has been associated with improved
outcomes
C 66-69 Greater than 8  106 CD34þ cells/kg is better, but a direct
comparison cannot be made.
(continued on next page)
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H.K. Duong et al. / Biol Blood Marrow Transplant 20 (2014) 1262e12731266engraftment, lower transplant-related mortality, and
reduced risk of relapse. However, not all these studies
demonstrated an improvement in overall survival because of
increased risk of GVHD [25-27]. In the ﬁrst report, 181 pa-
tients with hematologic malignancies received a range of
conditioning regimens, and CD34þ cell doses > 8  106/kg
were associated with more rapid neutrophil engraftment but
also with development of extensive chronic GVHD. There
was no impact on survival, relapse, or acute GVHD [25]. A
second study ofmyeloablative conditioning similarly showed
that CD34þ cell doses > 8.3  106 cells/kg were associated
with more frequent extensive chronic GVHD [26]. In the
third study by a cooperative group, 253 patients received
reduced-intensity conditioning, and total nucleated cell
doses > 9.1  108/kg, rather than higher CD34þ cell dose,
were associated with a higher incidence of chronic GVHD,
improved leukemia-free survival, and trend toward lower
relapse [27]. For matched sibling donor transplants it is
important to balance the beneﬁts of faster engraftment with
the higher risk for extensive chronic GVHD.
For matched unrelated donor transplants, higher cell
doses have not been clearly associated with higher risk of
GVHD [28-32]. A study of 932 patients from the NMDP
showed that regardless of conditioning regimen intensity, a
CD34þ cell dose between 4.5 and 9.5  106/kg was an inde-
pendent predictor of improved overall survival. Higher cell
doses did not result in greater incidence of acute or chronic
GVHD, and CD34þ cell doses above 9.5  106/kg did not
further improve outcomes [29].
Question 4: What are the target CD34þ cell doses for
collection and infusion for pediatric patients?
Pediatric-speciﬁc data on cell dose optimization is lack-
ing, and clinical practice has mainly been extrapolated from
adult data. In the few studies available, higher CD34þ cell
doses have been associated with faster engraftment but no
impact on overall survival or the risk for developing GVHD
[33-36].
Question 5: What type of venous access is recommended?
In several large retrospective reports of adult donor
populations, peripheral venous access was adequate for stem
cell collection in most patients. However, anywhere from .6%
to 20% of donors require central line placement. Line place-
ment was accomplished safely and effectively by interven-
tional radiology [37-41].
Pediatric donors generally require central venous cath-
eter placement. However, in a report from the Pediatric
Blood and Marrow Transplant Consortium of 218 collections,
33% of donors between ages 7 and 12 years could be collected
with peripheral access. For this reason, younger donors
should be carefully evaluated for this possibility. Potential
complications from catheter placement using general anes-
thesia or conscious sedation appear to be limited and mild
[19,20].
Autologous Progenitor Cell Transplant
Question 1: What is the optimal myeloid growth factor and
dose schedule for initial mobilization for adult patients?
If using growth factors alone, the standard is G-CSF. A
daily dose of 10 mg/kg/day, as a single subcutaneous injec-
tion, is most commonly used, with leukapheresis beginning
on the ﬁfth day [42-44]. No advantage has been shown by
split dosing G-CSF [45,46]. There is emerging data on the
efﬁcacy of 12 mg pegﬁlgrastim as a single subcutaneous dose
Table 3
Considerations for Special Populations, Comorbidities, and Other Topics
Recommendation Strength of
Recommendation
References Comments
Patients at high risk of stem cell mobilization
failure or for remobilization attempt
High-risk patients:
Upfront use or addition of plerixafor or chemotherapy
mobilization during initial mobilization
C 81-88 Many centers have developed algorithms based on risk for
stem cell mobilization failure.
Large-volume leukapheresis C 89-93 Algorithms need to be based on institutional resources.
For those who have failed initial mobilization attempt:
Plerixafor þ growth factors
Chemotherapy þ growth factors
C 94-97 A rest period of 2-4 wk is recommended before
remobilization attempt. Subsequent remobilization can be
successful with either addition of plerixafor or
chemotherapy plus growth factor. Success rates are much
higher with plerixafor plus growth factors.
Pediatric patients with low weight Patients below 15 kg are generally transfused to achieve
hemoglobin > 12 g/dL and platelet count > 40  109/L
C 98,99 PBSC harvesting from low-weight patients is safe and
effective.
Priming of the apheresis machine with either RBCs and/or
albumin is important for patients who weigh < 20 kg
C 19, 98,99 Priming of the machine compensates for extracorporeal
volume and mitigates hemodynamic complications.
Large volume leukapheresis (>3 times total blood volume)
can be performed in patients with low birth weight
C 100
Obese patients Single daily dosing G-CSF results in improved collection C 101 Further studies are needed before suggesting a maximum
dose of growth factor.Increased BMI does not impair ability to collect adequately
with plerixafor and G-CSF
C 102
Should dosing be according to ideal or actual
body weight?
Not yet enough data to recommend one approach over the
other
C 28, 103 Further studies are warranted; however, if necessary to
proceed with transplant, basing cell dose on either may be
acceptable.
How to address thrombocytopenia? For allogeneic stem cell donors:
Maximum of 2 d of collection and possible transfusion for
postapheresis platelet count <75  109/L.
C 37 Very little data for recommendations
For autologous stem cell transplant:
Transfuse for preapheresis platelet count below 30  109/L
to prevent bleeding complications.
C 90
Is there a threshold for leukocytosis for which
growth factors should be held?
No recommendation, but general practice for many centers
is to withhold G-CSF when WBC > 100  109/L and to hold
plerixafor when WBC > 75  109/L
C 37, 105-109 Theoretical concern is for splenic rupture, but very few data
support the recommendations. In case reports where
splenic rupture did occur, patients had WBC > 70  109/L.
However, no study has correlated WBC with risk for splenic
rupture. Despite that, G-CSF and plerixafor are typically held
at these thresholds.
Are G-CSF biosimilars recommended for use in
PBPC mobilization?
Currently, there are insufﬁcient data for recommending the
use of G-CSF biosimilars for PBPC mobilization.
C 112-114
IEV indicates ifosfamide, epirubicin, etoposide; ESHAP, etoposide, methylprednisolone, cytarabine, cisplatin; ICE, ifosfamide, carboplatin, etoposide.
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H.K. Duong et al. / Biol Blood Marrow Transplant 20 (2014) 1262e12731268[47]. However, pegﬁlgrastim has not been adopted by many
centers, likely because of ease and familiarity of use with
G-CSF and cost.
The greater effectiveness of plerixafor in combination
with G-CSF compared with G-CSF alonewas demonstrated in
separate randomized studies of patients with lymphoma and
myeloma [48,49]. Plerixafor has been approved by the US
Food and Drug Administration for use in conjunction with
G-CSF for the mobilization of PBPCs for autologous HCT in
patients with multiple myeloma and non-Hodgkin lym-
phoma. Because of its expense, many centers have adopted
algorithms favoring pre-emptive addition of plerixafor as a
salvage method, and it is uncommonly planned for initial
mobilization. For chemotherapy plus growth factor mobili-
zation, G-CSF 5 to 10 mg/kg/day as a single daily dose or
pegﬁlgrastim as a single administration can be used with
leukapheresis beginning when peripheral blood CD34þ
(pbCD34þ) cell count or WBC count is adequate (refer to
Question 7 below) [51-57].
Question 2: What type of chemotherapy and dose are
recommended for chemomobilization in adult patients?
Chemotherapy-induced mobilization is generally success-
ful during WBC recovery after disease-speciﬁc chemotherapy
[51-54]. In the absence of speciﬁc protocol-driven chemo-
therapy, cyclophosphamide or etoposide are commonly used
for mobilization and result in higher collection yields with
fewer days of apheresis than mobilizationwith growth factor
alone. Current data do not support the concern that mobili-
zation regimens that include etoposide promote secondary
malignancies [57]. However, these beneﬁts occur at the
expense of increased hospitalizations for neutropenic fever,
which occur in a substantial portion of patients [55-57].
Question 3: What is the optimal myeloid growth factor and
dose schedule for initial mobilization in pediatric patients?
For mobilization with growth factor alone, the most
commonly used regimen is daily G-CSF (10 mg/kg/day) with
leukapheresis beginning on the ﬁfth day of G-CSF. There is a
paucity of data in children regarding dose and scheduling of
growth factor alone [58,59]. Sevilla et al. [59] reported that
G-CSF 12 mg/kg given twice daily could result in successful
1-day collections. However, side effects appeared to be more
frequent than when lower doses were used. More recently,
case reports have indicated successful stem cell collections
using plerixafor and ﬁlgrastim, but existing data are insufﬁ-
cient to provide speciﬁc recommendations [60].
For chemotherapy plus growth factor mobilization, both
ﬁlgrastim and pegﬁlgrastim have been studied. Although
reports indicate similar efﬁcacy and side effect proﬁles for
both, ﬁlgrastim is generally used [61-63].
Question 4: What type of chemotherapy and dose are
recommended for chemomobilization in pediatric patients?
For children undergoing autologous PBPC collection,
mobilization is generally achieved during the marrow re-
covery phase after disease-speciﬁc chemotherapy protocols
[62,63].
Question 5: What are the target goals for collection for adult
and pediatric patients?
Studies have not demonstrated an absolute threshold cell
dose below which hematopoietic recovery will not occur.
However, a dose of 2  106 CD34þ cells/kg for a single
transplant has generally been accepted as a safe minimum.Lower doses have been used, but at the risk of delayed
neutrophil and platelet engraftment. Several studies have
demonstrated that the optimal number may be greater than
5  106 CD34 þ cells/kg [64,65]. Higher cell numbers from
so-called supermobilizers have been associated with faster
hematopoietic recovery, more robust long-term platelet
recovery, and improved overall survival [66-69]. In these
studies, CD34þ cell doses exceeding 8  106 CD34þ cells/kg
appeared to be associated with greater beneﬁt. However,
these studies are retrospective and have potential bias.
Studies are underway to address the question of whether it is
the ability to mobilize a higher number of stem cells or the
infused CD34 cell dose that is most important.
Question 6: When should you begin monitoring peripheral
blood CD34þ cell counts?
Mobilization with G-CSF alone causes pbCD34þ cell
counts to peak in the blood between the fourth and sixth
days of therapy. For this reason, pbCD34þ cell monitoring
should begin on either day 4 or 5 [5,70].
For patients mobilized with chemotherapy and growth
factor, pbCD34þ counts generally begin 8 to 10 days after
chemotherapy administration, when CD34þ cell counts are
expected to peak [51-57,71,72]. Peak timing varies according
to the speciﬁc chemotherapy regimen used and to patient-
speciﬁc factors. For patients mobilized with plerixafor plus
G-CSF in phase III studies, pbCD34þ cell counts were checked
on days 4 and 5 of G-CSF administration (see Table 2) [48,49].
Question 7: When should leukapheresis be initiated?
Leukapheresis is most commonly initiated on day 5 when
mobilization is achieved with G-CSF alone or G-CSF plus
plerixafor [5,43-45,70]. When mobilization is achieved with
chemotherapy, the start of leukapheresis is commonly
determined by a threshold pbCD34þ cell count. There is no
consensus on the optimal threshold, and institutional prac-
tice has varied from a minimal pbCD34þ count of 5 to 20/mL.
One retrospective study of 95 patients found that a minimal
pbCD34þ cell count of 5 cells/mL was adequate to meet a
speciﬁed collection goal; however, that goal of .75  106 or
1.25  106 CD34þ cells/kg is considered to be low [70].
Another study of 48 patients suggested that a pbCD34þ cell
count of at least 15 cells/mL was adequatewhen the collection
goal was only 1.5  106 CD34þ cells/kg [71]. A more common
target collection goal is at least 2  106 CD34þ cells/kg, and
Elliot et al. [72] reported that more than 90% of 39 study
patients achieved this goal when the threshold pbCD34þ cell
count for starting leukapheresis exceeded 20 cells/mL.
Considerations for Special Populations, Comorbidities,
and Other Topics
Question 1: What are possible ways to identify and address
patients at high risk for stem cell mobilization failure?
What is the preferred agent for remobilization attempt?
Gertz et al. [73] reported on 1775 patients who were mobi-
lized over a 7-year period. Patients were classiﬁed according
to CD34þ cell yield: optimal collection (5106 CD34þ cells/
kg), low collection (2 to <5  106 CD34þ cells/kg), poor
collection (<2  106 CD34þ cells/kg), and failed collection
(apheresis not attempted because of low peripheral
pbCD34þ cell count). Less than optimal collections were
observed for 47% of patients, among whom 37% proceeded to
transplant and the other 63% went on to further mobilization
attempts. With subsequent attempts, there was increased
use of growth factor support, antibiotic use, and transfusions,
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with stem cell mobilization failures [73].
Multiple studies have analyzed poor mobilizers and have
identiﬁed age greater than 60 years, multiple chemotherapy
regimens, prior exposure to alkylating therapy or prior ra-
diation, prior treatment with lenalidomide, and platelet
count below 100  109/L [65,73-76]. Once mobilization has
begun, other factors include low pbCD34þ cell count and
poor collection on day 1 [77,78]. Therefore, many programs
have developed algorithms to identify high-risk populations
and to initiate rescue therapy during the ﬁrst mobilization
attempt to increase the likelihood of success [77-87]. The
practice of escalating G-CSF doses to 20 to 30 mk/kg/day,
when patients are not ready for collection 12 or 13 days after
chemotherapy plus G-CSF at 10 mg/kg/day, is expensive and
generally unsubstantiated. Similarly, data are insufﬁcient in
this scenario to support a day 12 or 13 rescue dose of pler-
ixafor [88,89]. These risk-adapted strategies have not yet
been validated, and further studies are needed.
Another strategy that has improved cell collection yield is
large-volume leukapheresis [90-94]. For patients who fail an
initial mobilization attempt, a rest period of 2 to 4 weeks is
generally recommended before a subsequent attempt.
Growth factors alone are generally not successful. Even
combination growth factor support results in failure rates in
excess of 80%. Chemotherapy with growth factor support
also results in higher than desired failure rates and with
more toxicities [95]. Plerixafor plus G-CSF (without chemo-
therapy) results in the highest success when used in the
standard manner and is the preferred approach [96,97].
Question 2: How do you address pediatric patients with low
weight?
One of the main concerns regarding pediatric patients
with low body weight is the associated low blood volume. A
low extracorporeal volume is necessary to mitigate hemo-
dynamic complications. Patients of low weight should have
hemoglobin of at least 12 g/dL or should be transfused
with RBCs to reach this level [98]. Similarly, when severe
thrombocytopenia is present, platelet transfusion to above
40  109/L is recommended to prevent bleeding complica-
tions. In children who weigh less than 20 kg, the apheresis
machine should be primedwith RBCs and/or human albumin
to lower the extracorporeal volume [19,99].
Question 3: Are there special considerations for obese
patients?
There are little data to address growth factor dosing in
obese patients. One retrospective study of 86 patients
reviewed outcomes after 2 different G-CSF mobilization
regimens: either single daily dose (14 mg/kg/day) or split
dose (2  7 mg/kg/day). Patients were stratiﬁed according to
body mass index (BMI; 25 or >25). In patients with BMI
> 25 kg/m2, once-daily dosing resulted in a higher CD34þ cell
yield [101]. Another retrospective study of 356 patients
found that BMI  25 did not affect the CD34þ cell yields
when mobilization was achieved by plerixafor plus G-CSF.
Although not statistically signiﬁcant, there was a trend that
patients with higher BMI required more apheresis sessions
and a higher total dose of plerixafor, but this could possibly
be overcome if plerixafor dose and/or CD34þ dose were ac-
cording to ideal and not actual body weight [102].
Waples et al. [103] performed a retrospective analysis
comparing PBPC dosing by ideal versus actual body weight.
In 63 patients who underwent progenitor cell mobilizationwith chemotherapy and G-CSF, 49% were greater than 25%
over their ideal body weight. In this study, higher cell doses
were associated with improved hematopoietic recovery,
regardless of whether ideal or actual body weight calculation
were used. Also, 16% of patients would have had 1 less
apheresis procedure performed if ideal weight were used.
More recently, Pulsipher et al. [29] also reported that similar
outcomes in adult patients whether CD34þ cell dose was
based on actual or ideal body weight. Although other un-
published NMDP data also suggest that dosing obese patients
according to ideal body weight might be sufﬁcient, addi-
tional studies are needed before this becomes a recom-
mended standard practice [103]. Further evaluation of effects
on G-CSF, CD34þ cell dosing, and body weight may be of
increasing importance as a cost-saving measure.
Question 4: How do you manage thrombocytopenia?
Leukapheresis procedures usually result in a decrease in
platelet count. Although some variability may exist in the
extent of platelet loss depending on the type of apheresis
machine, this occurs because of an inability to completely
separate platelets from the target cell layer in the centrifuge.
This, coupled alongwith the anticoagulants necessary for the
extracorporeal circuit, may increase bleeding risk in patients
who begin their collection with thrombocytopenia [90].
For allogeneic donors, safety is of primary concern. Among
2408 unrelated donors from the NMDP, after 2 days of
collection nearly 40% had platelet counts below 100  109/L
and 2% had platelet counts below 50  109/L (with a single
donor having a platelet count below 20  109/L) [37]. The
NMDP recommends that unrelated donors not undergo leu-
kapheresis for more than 2 days. Furthermore, the safety of
continuing leukapheresis must be carefully considered if the
platelet count falls below <100  109/L [104]. Similar stan-
dards should be considered for adult related donors.
Question 5: Is there is a threshold of leukocytosis for which
growth factor should be held?
There are minimal data to guide the management of
mobilization in patients who have leukocytosis. The risk of
growth factoreinduced splenic rupture is an important
concern. In the report on 2408 donors from the NMDP, nearly
a third developed WBC blood counts exceeding 50  109/L,
but fewer than 1% had WBC counts exceeding 75  109/L.
There was no splenic rupture or thrombosis [37].
However, several isolated case reports describe donors
who had splenic rupture in whomWBC counts at the time of
the event exceeded 50  109/L [105-107]. In a report on 91
donors that assessed splenic size by ultrasound and palpa-
tion during G-CSF mobilization, a signiﬁcant increase in
spleen size was observed, but there was no correlation with
any hematologic parameters and no splenic complications
[108]. More recently, Stiff et al. [109] reported on 306 donors
undergoing G-CSF mobilization and splenic assessments
performed by ultrasound and physical exam. The median
spleen volume increased by 1.47-fold on the ﬁrst day of
leukapheresis but declined to near pretreatment size by
7 days after leukapheresis. In only 9% of patients did splenic
volumes increase bymore than 2-fold. There were no splenic
ruptures. There was no correlation between change in
spleen volume, G-CSF dose, peak absolute neutrophil count,
CD34þ cell yield, or donor weight [109]. Despite the lack of
association between hematologic parameters and splenic
enlargement or risk of splenic rupture, the general practice is
to withhold G-CSF when theWBC count exceeds 100  109/L
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Question 6: Are G-CSF biosimilars recommended for use in
PBPC mobilization?
Approved biosimilar G-CSFs are produced and manufac-
tured by a similar process to the innovator (original) biologic
and generally sold at lower prices. Data support their role in
chemotherapy-induced neutropenia with cost efﬁciency
[110,111]; however, less data are available regarding their use
in PBSCmobilization [112-114]. Lefrere et al. [112] reported on
their ﬁrst experience in 40 patients undergoing mobilization
with biosimilar G-CSF. Compared with a historical cohort
group treated with G-CSF, there were no signiﬁcant differ-
ences in median CD34þ cell collection. Schmitt et al. [113]
recently reported comparable efﬁcacy and safety in 22
healthy donors using aG-CSF biosimilar XM02 comparedwith
G-CSF. In another retrospective, single-institution study of 96
patients comparing ﬁlgrastim, biosimilar ﬁlgrastim, and
lenograstim, biosimilar ﬁlgrastimwas found to be comparable
with ﬁlgrastim for collection yields [114]. Larger controlled
studies with longer term follow-up are necessary before rec-
ommending the use of these agents for mobilization.
CONCLUSIONS
Hematopoietic progenitor cell mobilization and collection
is an evolving area with wide variation in clinical practice.
Although each institution varies according to patient de-
mographics, ﬁnancial limitations, and resource availability,
the American Society for Blood and Marrow Transplantation
Practice Guidelines Subcommittee developed this “frequently
asked question” style review with the goal to provide trans-
plant practitioners with straightforward consensus and
evidence-driven practice guidelines.
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IN CLINICAL GUIDELINES [1]
Levels of Evidence
1þþ High-quality meta-analyses, systematic reviews of
RCTs or RCTs with a very low risk of bias
1þ Well-conducted meta-analyses, systematic reviews
of RCTs, or RCTs with a low risk of bias
1- Meta-analyses, systematic reviews of RCTs, or RCTs
with a high risk of bias
2þþ High-quality systematic reviews of case-control or
cohort studies; high-quality case-control or cohort
studies with a very low risk of confounding, bias, or
chance and a high probability that the relationship
is causal
2þ Well-conducted case-control or cohort studies
with a low risk of confounding, bias, or chance
and a moderate probability that the relationship is
causal
2- Case-control or cohort studies with a high risk of
confounding, bias, or chance and a signiﬁcant risk
that the relationship is not causal3 Nonanalytic studies, eg, case reports or case series
4 Expert opinion
Grades of Recommendation
A At least 1 meta-analysis, systematic review, or RCT
rated as 1þþ and directly applicable to the target
population or a systematic review of RCTs or a body of
evidence consisting principally of studies rated as 1þ,
directly applicable to the target population, and
demonstrating overall consistency of results
B A body of evidence including studies rated as 2þþ,
directly applicable to the target population, and
demonstrating overall consistency of results or
extrapolated evidence from studies rated as 1þþ or 1þ
C A body of evidence including studies rated as 2þ,
directly applicable to the target population, and
demonstrating overall consistency of results or
extrapolated evidence from studies rated as 2þþ
D Evidence level 3 or 4 or extrapolated evidence from
studies rated as 2þ
RCT indicates randomized clinical trial.
